ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,304.72
      0.70%
      US Tech 100
      18,318.00
      0.95%
      Dow Jones
      39,069.59
      0.01%
      Brent Oil
      81.965
      0.00%
      Bitcoin
      69,184.95
      -0.12%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Corvus Pharmaceuticals Inc (CRVS)

      7. Corvus Pharmaceuticals Inc (CRVS) News

      CRVS

      Corvus Pharmaceuticals (CRVS)

      Corvus Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CRVS
      DateTimeSourceHeadlineSymbolCompany
      05/07/20245:19PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CRVSCorvus Pharmaceuticals Inc
      05/07/20245:16PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRVSCorvus Pharmaceuticals Inc
      05/07/20245:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
      05/06/20244:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
      05/06/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
      05/06/20244:01PMGlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
      05/02/20244:02PMGlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024NASDAQ:CRVSCorvus Pharmaceuticals Inc
      05/02/20248:30AMGlobeNewswire Inc.Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct OfferingNASDAQ:CRVSCorvus Pharmaceuticals Inc
      04/09/20244:01PMGlobeNewswire Inc.Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisNASDAQ:CRVSCorvus Pharmaceuticals Inc
      03/19/20244:02PMGlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
      03/19/20247:27AMIH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:CRVSCorvus Pharmaceuticals Inc
      03/13/20244:02PMGlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024NASDAQ:CRVSCorvus Pharmaceuticals Inc
      03/01/20245:57PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
      02/12/20248:30AMGlobeNewswire Inc.Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory DiseasesNASDAQ:CRVSCorvus Pharmaceuticals Inc
      02/08/20244:27PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
      02/08/20244:05PMGlobeNewswire Inc.Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell LymphomaNASDAQ:CRVSCorvus Pharmaceuticals Inc
      02/06/20244:05PMGlobeNewswire Inc.Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business OfficerNASDAQ:CRVSCorvus Pharmaceuticals Inc
      01/23/20245:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
      01/23/20245:00PMGlobeNewswire Inc.Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. MitchellNASDAQ:CRVSCorvus Pharmaceuticals Inc
      12/09/202312:00PMGlobeNewswire Inc.Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma TrialNASDAQ:CRVSCorvus Pharmaceuticals Inc
      12/08/20234:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
      12/08/20234:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
      11/07/20234:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
      11/07/20234:02PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRVSCorvus Pharmaceuticals Inc
      11/07/20234:01PMGlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
      11/02/20239:15AMGlobeNewswire Inc.Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & ExpositionNASDAQ:CRVSCorvus Pharmaceuticals Inc
      11/01/20237:31PMGlobeNewswire Inc.Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune DiseasesNASDAQ:CRVSCorvus Pharmaceuticals Inc
      10/31/20234:02PMGlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023NASDAQ:CRVSCorvus Pharmaceuticals Inc
      09/06/20234:05PMGlobeNewswire Inc.Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDANASDAQ:CRVSCorvus Pharmaceuticals Inc
      08/08/20234:02PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRVSCorvus Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:CRVS